
JNJ-7706621
CAS No. 443797-96-4
JNJ-7706621( JNJ7706621 | JNJ 7706621 )
Catalog No. M14517 CAS No. 443797-96-4
A dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 55 | In Stock |
![]() ![]() |
5MG | 96 | In Stock |
![]() ![]() |
10MG | 170 | In Stock |
![]() ![]() |
25MG | 268 | In Stock |
![]() ![]() |
50MG | 492 | In Stock |
![]() ![]() |
100MG | 690 | In Stock |
![]() ![]() |
500MG | 1395 | In Stock |
![]() ![]() |
1G | Get Quote | In Stock |
![]() ![]() |
Biological Information
-
Product NameJNJ-7706621
-
NoteResearch use only, not for human use.
-
Brief DescriptionA dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM).
-
DescriptionA dual CDK/Aurora kinase inhibitor with IC50 of 9/4/11/15 nM for CDK1/CDK2/Aurora A/Aurora B respectively; also exhibits activity towards CDK3, CDK4, and CDK6 (IC50s=50-250 nM), and no activity for Plk1 or Wee1; arrests the cell cycle at the G2-M phase; shows significant antitumor activity in tumor xenograft model.
-
In Vitro——
-
In Vivo——
-
SynonymsJNJ7706621 | JNJ 7706621
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorAuroraA|AuroraB|CDK1/CyclinB|CDK2/CyclinA|CDK2/CyclinE
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number443797-96-4
-
Formula Weight394.356
-
Molecular FormulaC15H12F2N6O3S
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=S(C1=CC=C(NC2=NN(C(C3=C(F)C=CC=C3F)=O)C(N)=N2)C=C1)(N)=O
-
Chemical NameBenzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Emanuel S, et al. Cancer Res. 2005 Oct 1;65(19):9038-46.
2. Huang S, et al. Bioorg Med Chem Lett. 2006 Jul 15;16(14):3639-41.
3. Seamon JA, et al. Mol Cancer Ther. 2006 Oct;5(10):2459-67.
molnova catalog



related products
-
HSD992
HSD992 is a potent, selective CDK2/3 inhibitor with moderate CDK9 inhibition with IC50 of 18 nM, 57 nM and 49 nM for CDK3/cyclin E, CDK2/cyclin A1 and CDK2/cyclin E, respecively.
-
ON123300
ON123300 is a potent, multi-targeted kinase inhibitor with IC50 of 5, 3.9, 26, 26, 9.2 and 11 nM for ARK5, CDK4, PDGFRβ, FGFR1, RET and FYN, respectively.
-
Ro-3306
RO-3306 is an ATP-competitive inhibitor, and inhibits CDK1/cyclin A complexes with Ki of 110 nM. RO-3306 blocks the cell cycle in the G2/M phase of human cancer cells.